Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

44.29 +0.94 (+2.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,182,236
Open 43.50
Bid (Size) 43.70 (10)
Ask (Size) 45.23 (1)
Prev. Close 43.35
Today's Range 43.40 - 44.52
52wk Range 32.83 - 46.16
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily

Performance

YTD
+18.45%
+18.45%
1 Month
+13.22%
+13.22%
3 Month
+9.20%
+9.20%
6 Month
+9.68%
+9.68%
1 Year
+29.69%
+29.69%

More News

Read More
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Expert Ratings For Halozyme Therapeutics
Via Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Via Chartmill
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
Via Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.